JAKi in inflammatory myositis? #ACR24 will showcase nearly 3000 abstracts. With the expanding use of JAK inhibitors, there will be some interesting presentations for off label use. There have been some uncontrolled data that tofacitinib reduced inflammatory myositis disease… https://t.co/SnqvElwk0B https://t.co/A5mJbpmB5P

Finding the Right Combination Therapy in RA Dr. Jonathan Kay interviews Dr. Ernest Choy about abstract 0521, Transcriptome Analysis of Drug Response in a Large Cohort of Immune-Mediated Inflammatory Disease Patients Supports Advanced Combination Therapy in RA, presented at… https://t.co/yPmDIZ6aKI https://t.co/cairKrbDDu

#Ianalumab 300 mg sc q monthly B cell depleted and changes BAFF signalling 👇⬇️IFN May be promising in #lupus #SLE +data in primary #Sjogrens ACR24 @RheumNow @ACRheum Abst#2425 Needs Phase3 ➡️I suspect safer than CAR T and Bispecific T cell engagers but ? ⬇️efficacy

ACR24 take homes ➡️#Inflammatory #myositis #Upadacitinib improved MDA5 ILD #Baricitinib 4mg/d good in myositis delayed start #RCT #Tofacitinb ➡️help for skin, calcinosis, rash in case series ➡️RCT ongoing JAKi is ‘jacked’ in muscles 💪🏿 #ACR24 @RheumNow @ACRheum 1731 0348

Late breaking abstract L17 CAR-NK Therapy for Refractory SLE. In a trial of 20 severe SLE patients: - 75% achieved LLDAS, 50% achieved DORIS remission at 6 months - B cell reconstitution: 2–3 months post-treatment - Safety: 2 mild cytokine release syndrome with fever; no severe… https://t.co/MS8cutm48o

• https://x.com/i/web/status/1858887962349760575

In Vivo CAR T Cell Therapy. A single intralymphatic injection of VivoVec™ particles: - Generates functional CAR T cells in vivo - Achieves complete B cell depletion in NHPs without lymphodepletion - Demonstrates potential for an off-the-shelf solution for autoimmune disease… https://t.co/5DTzRvZjbY https://t.co/DvTOqnhn1V

• https://x.com/i/web/status/1858891733259427881
• https://x.com/synovialjoints/status/1858891733259427881/photo/1

🚨 New SLE treatment update! 🚨 Dapirolizumab pegol (DZP), novel CD40L inhibitor, for moderate-to-severe lupus. Phase 3 trial, DZP reduced disease activity, helped taper steroids, and achieved a higher BICLA Safe and generally well tolerated! #ACR24 #L16 @rheumnow https://t.co/lFrKjz4CZ1

• https://x.com/bella_mehta/status/1858893243057897860/photo/1